Royalty Pharma (RPRX) Operating Income (2019 - 2026)

Royalty Pharma has disclosed Operating Income across 8 years of filings, most recently posting $133.1 million for Q2 2026.

• In Q2 2026, Operating Income fell 36.55% year-over-year to $133.1 million; the TTM figure through Jun 2026 stood at $1.5 billion (down 17.87% YoY), while the FY2025 annual figure was $1.6 billion, up 20.66% from the prior year.
• Operating Income came in at $133.1 million for Q2 2026 at Royalty Pharma, down from $563.0 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $735.1 million in Q3 2024 to a low of -$482.7 million in Q4 2022.
• Average Operating Income over 5 years is $297.1 million, with a median of $315.6 million recorded in 2024.
• Year-over-year, Operating Income tumbled 414.6% in 2022 and jumped 824.08% in 2025.
• Over 5 years, Operating Income stood at -$482.7 million in 2022, then soared by 226.98% to $612.9 million in 2023, then tumbled by 41.02% to $361.5 million in 2024, then grew by 7.43% to $388.4 million in 2025, then slumped by 65.72% to $133.1 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were $133.1 million in Q2 2026, $563.0 million in Q1 2026, and $388.4 million in Q4 2025.